REMSleep Holdings Launches DeltaWave™ Nasal Pillow System Nationwide Following Regulatory Approvals

REMSleep Holdings, Inc. has announced the full commercial launch of its DeltaWave™ nasal pillow system across all U.S. distribution channels, including durable medical equipment companies and institutional sales. This launch follows the completion of regulatory prerequisites, including expanded FDA 510(k) clearance secured on January 15 and Medicare PDAC coding approval for every product configuration on January 21. The company has been building infrastructure since December 2025, activating enterprise ERP systems, deploying a nationwide independent sales force across 48 states, and receiving product inventory.

The DeltaWave Nasal Pillow System features patented Direct Airflow Technology designed to reduce the pressure and airflow sensation patients experience at the nasal interface. This engineering approach addresses the therapy compliance problem in sleep medicine, where 30 to 50 percent of patients prescribed CPAP therapy abandon it within the first year, with mask discomfort consistently cited as a primary reason. The full commercial portfolio includes a Starter Kit with all three nasal pillow sizes, Single Pillow Systems for resupply, Nasal Interface configurations without headgear, and a complete accessories suite.

The expanded FDA clearance broadens DeltaWave's indicated use to BiPAP, institutional settings, hospitals, long-term care facilities, and sleep labs, opening channels that were previously inaccessible under the original 510(k) language. These institutional channels often introduce solutions to patients at the beginning of therapy, creating downstream revenue opportunities for DME partners as patients continue to reorder products they find comfortable. PDAC coding approvals cover every configuration for Medicare and private payor billing, enabling DME providers to incorporate DeltaWave into their product mix with proper reimbursement mechanisms.

Thomas Wood, CEO and Founder, emphasized that the product was designed from inception to provide patients with a more comfortable breathing experience to improve therapy adherence. The company's positioning of DeltaWave as a rescue mask alternative gives providers a clinically differentiated option when standard formularies prove ineffective for patients. DME providers now have access to codes, inventory, and clinical rationale to integrate this solution into their offerings. The launch represents the culmination of a three-year development process that included FDA clearance, patent protection, clinical testing, and operational infrastructure development.

REMSleep will continue providing operational updates as commercialization progresses through the first and second quarters of 2026. The DeltaWave system is available through the company's direct sales channels, with product specifications, pricing, and ordering information accessible at https://www.remsleep.com. This nationwide availability marks a significant milestone in addressing persistent compliance challenges in positive airway pressure therapy through innovative medical device technology.